1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 OBJECTIVES OF THE STUDY
2.2 STAKEHOLDERS
2.3 DATA SOURCES
2.3.1 PRIMARY SOURCES
2.3.2 SECONDARY SOURCES
2.4 MARKET ESTIMATION
2.4.1 BOTTOM-UP APPROACH
2.4.2 TOP-DOWN APPROACH
2.5 FORECASTING METHODOLOGY
3 EXECUTIVE SUMMARY
4 JAPAN BIOSIMILAR MARKET - INTRODUCTION
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.3 INDUSTRY TRENDS
4.4 COMPETITIVE INTELLIGENCE
5 JAPAN BIOSIMILAR MARKET LANDSCAPE
5.1 HISTORICAL AND CURRENT MARKET TRENDS
5.2 MARKET FORECAST (2025-2033)
6 JAPAN BIOSIMILAR MARKET - BREAKUP BY PRODUCT
6.1 MONOCLONAL ANTIBODIES
6.1.1 OVERVIEW
6.1.2 HISTORICAL AND CURRENT MARKET TRENDS
6.1.3 MARKET FORECAST (2025-2033)
6.2 RECOMBINANT HORMONES
6.2.1 OVERVIEW
6.2.2 HISTORICAL AND CURRENT MARKET TRENDS
6.2.3 MARKET FORECAST (2025-2033)
6.3 IMMUNOMODULATORS
6.3.1 OVERVIEW
6.3.2 HISTORICAL AND CURRENT MARKET TRENDS
6.3.3 MARKET FORECAST (2025-2033)
6.4 ANTI-INFLAMMATORY AGENTS
6.4.1 OVERVIEW
6.4.2 HISTORICAL AND CURRENT MARKET TRENDS
6.4.3 MARKET FORECAST (2025-2033)
7 JAPAN BIOSIMILAR MARKET - BREAKUP BY APPLICATION
7.1 BLOOD DISORDERS
7.1.1 OVERVIEW
7.1.2 HISTORICAL AND CURRENT MARKET TRENDS
7.1.3 MARKET FORECAST (2025-2033)
7.2 GROWTH HORMONAL DEFICIENCY
7.2.1 OVERVIEW
7.2.2 HISTORICAL AND CURRENT MARKET TRENDS
7.2.3 MARKET FORECAST (2025-2033)
7.3 CHRONIC AND AUTOIMMUNE DISORDERS
7.3.1 OVERVIEW
7.3.2 HISTORICAL AND CURRENT MARKET TRENDS
7.3.3 MARKET FORECAST (2025-2033)
7.4 ONCOLOGY
7.4.1 OVERVIEW
7.4.2 HISTORICAL AND CURRENT MARKET TRENDS
7.4.3 MARKET FORECAST (2025-2033)
8 JAPAN BIOSIMILAR MARKET - BREAKUP BY DISTRIBUTION CHANNEL
8.1 HOSPITAL PHARMACIES
8.1.1 OVERVIEW
8.1.2 HISTORICAL AND CURRENT MARKET TRENDS
8.1.3 MARKET FORECAST (2025-2033)
8.2 RETAIL PHARMACIES
8.2.1 OVERVIEW
8.2.2 HISTORICAL AND CURRENT MARKET TRENDS
8.2.3 MARKET FORECAST (2025-2033)
8.3 ONLINE PHARMACIES
8.3.1 OVERVIEW
8.3.2 HISTORICAL AND CURRENT MARKET TRENDS
8.3.3 MARKET FORECAST (2025-2033)
9 JAPAN BIOSIMILAR MARKET – BREAKUP BY REGION
9.1 KANTO REGION
9.1.1 OVERVIEW
9.1.2 HISTORICAL AND CURRENT MARKET TRENDS
9.1.3 MARKET BREAKUP BY MOLECULE
9.1.4 MARKET BREAKUP BY INDICATION
9.1.5 MARKET BREAKUP BY MANUFACTURING TYPE
9.1.6 KEY PLAYERS
9.1.7 MARKET FORECAST (2025-2033)
9.2 KANSAI/KINKI REGION
9.2.1 OVERVIEW
9.2.2 HISTORICAL AND CURRENT MARKET TRENDS
9.2.3 MARKET BREAKUP BY MOLECULE
9.2.4 MARKET BREAKUP BY INDICATION
9.2.5 MARKET BREAKUP BY MANUFACTURING TYPE
9.2.6 KEY PLAYERS
9.2.7 MARKET FORECAST (2025-2033)
9.3 CENTRAL/ CHUBU REGION
9.3.1 OVERVIEW
9.3.2 HISTORICAL AND CURRENT MARKET TRENDS
9.3.3 MARKET BREAKUP BY MOLECULE
9.3.4 MARKET BREAKUP BY INDICATION
9.3.5 MARKET BREAKUP BY MANUFACTURING TYPE
9.3.6 KEY PLAYERS
9.3.7 MARKET FORECAST (2025-2033)
9.4 KYUSHU-OKINAWA REGION
9.4.1 OVERVIEW
9.4.2 HISTORICAL AND CURRENT MARKET TRENDS
9.4.3 MARKET BREAKUP BY MOLECULE
9.4.4 MARKET BREAKUP BY INDICATION
9.4.5 MARKET BREAKUP BY MANUFACTURING TYPE
9.4.6 KEY PLAYERS
9.4.7 MARKET FORECAST (2025-2033)
9.5 TOHOKU REGION
9.5.1 OVERVIEW
9.5.2 HISTORICAL AND CURRENT MARKET TRENDS
9.5.3 MARKET BREAKUP BY MOLECULE
9.5.4 MARKET BREAKUP BY INDICATION
9.5.5 MARKET BREAKUP BY MANUFACTURING TYPE
9.5.6 KEY PLAYERS
9.5.7 MARKET FORECAST (2025-2033)
9.6 CHUGOKU REGION
9.6.1 OVERVIEW
9.6.2 HISTORICAL AND CURRENT MARKET TRENDS
9.6.3 MARKET BREAKUP BY MOLECULE
9.6.4 MARKET BREAKUP BY INDICATION
9.6.5 MARKET BREAKUP BY MANUFACTURING TYPE
9.6.6 KEY PLAYERS
9.6.7 MARKET FORECAST (2025-2033)
9.7 HOKKAIDO REGION
9.7.1 OVERVIEW
9.7.2 HISTORICAL AND CURRENT MARKET TRENDS
9.7.3 MARKET BREAKUP BY MOLECULE
9.7.4 MARKET BREAKUP BY INDICATION
9.7.5 MARKET BREAKUP BY MANUFACTURING TYPE
9.7.6 KEY PLAYERS
9.7.7 MARKET FORECAST (2025-2033)
9.8 SHIKOKU REGION
9.8.1 OVERVIEW
9.8.2 HISTORICAL AND CURRENT MARKET TRENDS
9.8.3 MARKET BREAKUP BY MOLECULE
9.8.4 MARKET BREAKUP BY INDICATION
9.8.5 MARKET BREAKUP BY MANUFACTURING TYPE
9.8.6 KEY PLAYERS
9.8.7 MARKET FORECAST (2025-2033)
10 JAPAN BIOSIMILAR MARKET – COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 MARKET STRUCTURE
10.3 MARKET PLAYER POSITIONING
10.4 TOP WINNING STRATEGIES
10.5 COMPETITIVE DASHBOARD
10.6 COMPANY EVALUATION QUADRANT
11 PROFILES OF KEY PLAYERS
11.1 NOVARTIS AG
11.1.1 BUSINESS OVERVIEW
11.1.2 PRODUCT PORTFOLIO
11.1.3 BUSINESS STRATEGIES
11.1.4 SWOT ANALYSIS
11.1.5 MAJOR NEWS AND EVENTS
11.2 PFIZER INC.
11.2.1 BUSINESS OVERVIEW
11.2.2 PRODUCT PORTFOLIO
11.2.3 BUSINESS STRATEGIES
11.2.4 SWOT ANALYSIS
11.2.5 MAJOR NEWS AND EVENTS
11.3 AMGEN INC
11.3.1 BUSINESS OVERVIEW
11.3.2 PRODUCT PORTFOLIO
11.3.3 BUSINESS STRATEGIES
11.3.4 SWOT ANALYSIS
11.3.5 MAJOR NEWS AND EVENTS
11.4 COHERUS BIOSCIENCES, INC
11.4.1 BUSINESS OVERVIEW
11.4.2 PRODUCT PORTFOLIO
11.4.3 BUSINESS STRATEGIES
11.4.4 SWOT ANALYSIS
11.4.5 MAJOR NEWS AND EVENTS
11.5 VIATRIS INC
11.5.1 BUSINESS OVERVIEW
11.5.2 PRODUCT PORTFOLIO
11.5.3 BUSINESS STRATEGIES
11.5.4 SWOT ANALYSIS
11.5.5 MAJOR NEWS AND EVENTS
11.6 SAMSUNG BIOEPIS CO., LTD
11.6.1 BUSINESS OVERVIEW
11.6.2 PRODUCT PORTFOLIO
11.6.3 BUSINESS STRATEGIES
11.6.4 SWOT ANALYSIS
11.6.5 MAJOR NEWS AND EVENTS
12 JAPAN BIOSIMILAR MARKET - INDUSTRY ANALYSIS
12.1 DRIVERS, RESTRAINTS, AND OPPORTUNITIES
12.1.1 OVERVIEW
12.1.2 DRIVERS
12.1.3 RESTRAINTS
12.1.4 OPPORTUNITIES
12.2 PORTERS FIVE FORCES ANALYSIS
12.2.1 OVERVIEW
12.2.2 BARGAINING POWER OF BUYERS
12.2.3 BARGAINING POWER OF SUPPLIERS
12.2.4 DEGREE OF COMPETITION
12.2.5 THREAT OF NEW ENTRANTS
12.2.6 THREAT OF SUBSTITUTES
12.3 VALUE CHAIN ANALYSIS
13 APPENDIX
著作権 ©2022 無断複写・転載を禁じます
